weight loss and insulin sensitivity. Native GLP-1 has a potent blood glucose-lowering 110 action, mediated via its ability to induce insulin secretion and reduce glucagon 111 secretion in a glucose-dependent manner, as well as suppressing appetite and 112 delaying gastric emptying.
10 Endogenous GLP-1 is degraded within minutes in vivo by 113 the enzyme dipeptidyl peptidase-4, whereas liraglutide is a long-acting (half-life 13 114 hours) human GLP-1 analogue.
11 Liraglutide has been shown to cause weight loss, 12 115 decrease glycated haemoglobin (HbA1c) and systolic blood pressure and improve 116 beta-cell function, 13 and is licensed for glycaemic control in patients with type 2 117 diabetes. 118 119 GLP-1 analogues have been shown to reduce liver enzymes and oxidative stress as 120 well as improving liver histology 14 in murine models of NASH. [15] [16] [17] This may reflect 121 their effects on obesity and systemic insulin resistance, although studies have also 122
reported that GLP-1 analogues can act directly on human hepatocytes in vitro, to 123 reduce steatosis by decreasing de novo lipogenesis and increasing fatty acid 124 oxidation. 15, 18, 19 125 126
To date, human studies investigating the effect of GLP-1 analogues on liver injury 127 have been limited to case reports, 20 , 21 a case series (n=8) 22 and retrospective studies 128 of liver enzymes in patients with type 2 diabetes. 23, 24 However, these studies were 129 retrospective and lacked histological data, therefore we designed and conducted a 130 multi-centre randomised controlled trial of liraglutide to test its safety and efficacy in 131 
Participants: 154
All patients provided written informed consent. The trial entry criteria were based 155 on a diagnosis of 'definite' NASH on liver biopsy obtained within 6 months of 156 screening. Prior to randomisation, two independent liver histopathologists (SGH, RB) 157 reviewed all of the liver biopsies to confirm whether a diagnosis of 'definite' NASH 158 was present, as defined by macrovesicular steatosis (>5%), hepatocyte ballooning 159 (with confirmation of the presence of Mallory's Hyaline by ubiquitin 160 immunohistochemistry as necessary) and lobular inflammation (mixed infiltrate, 161 8 related to foci of ballooning). 26 In the event of disagreement with regards to a 162 diagnosis of 'definite' NASH, a combined assessment was undertaken to achieve 163 
Statistical analysis 227
The primary aim of the study was to assess whether the efficacy and safety profile of Both patients assigned to placebo that achieved histological improvement did not 317 have type 2 diabetes at baseline. The relative risk for non-diabetic patients achieving 318 the primary end-point was 3.4 (95% CI 0.8, 14.4; p=0.11) for liraglutide versus 319 placebo. As there were no patients with diabetes that responded in the placebo arm 320 a factor of 0.5 was added to all 4 values in the contingency table for diabetic 321 patients. Using this adjustment the relative risk for diabetic patients was calculated 322 as 4.7 (95% CI 0.3, 75.0; p=0.20). There was no evidence of heterogeneity (p=0.841). 323
The relative risk of response on liraglutide compared to placebo adjusted for 324 diabetes using the stratified Mantel-Haenszel test was 3.7 (95% CI 1.0, 13.5; 325 p=0.047). The study was appropriately powered for a hard histological end-point, and the level 418 of histological resolution of NASH with liraglutide (9 of 23; 39%) was comparable to 419 that previously reported with vitamin E (29 of 80; 36%), pioglitazone (33 of 70; 47%) 7 420 and obeticholic acid (22 of 102; 22%). 8 The reported placebo rate (9%) was slightly 421 lower than those previously described (13-21%), 7, 8 but this is likely because in this 422 study clearance of NASH had to be accompanied without any worsening of fibrosis 423 (which has not been previously adopted). Table 7 . 625
